Quantgene uses both deep genomics and AI to spot cancer at is beginning stages. This podcast investigates:
Quantgene founder and CEO Jo Bhakdi explains his company’s primary goal: to improve and achieve the earliest possible detection of multiple cancer varieties. The company engages a human genome sequence software-driven technology to achieve this aim. But they also use chemistry, machine learning, and laboratory processes to fine tune the process with extreme precision. The company can sequence cancer DNA one molecule at a time. Compared to more conventional blood testing such as protein marker detection, this process both escalates the timing and precision exponentially
Quantgene has a system refined by multiple means, including specialized straight tubing that cleans and purifies the blood. This elimination of blood “noise” means they can identify somatic DNA mutations before DNA-destroying enzymes interfere. Therefore, this human genome sequence effort is more exact and faster than next-generation sequencing.
The bioinformatics is a key element of this process and unique in human genome sequence work. Quantgene has created the world’s largest data set of tumor DNA. They can use this data to refine detection by identifying the smallest number of locations needed to still accurately identify any tumor variation. This means they can obtain a “systemic reflection of the tumor” and identify it exactly in mutational terms. This data aggregate has created a paradigm shift in oncology.
Future plans include the 2020 launch of a product called Serenity, an annual blood test that can help physicians detect cancer early. The resulting data will add to a growing conglomeration that will help long-term understanding of these cancers.
For more information on the company, see https://www.quantgene.com/
For more on the 2020 test release of Serenity, see https://www.quantgene.com/early-cancer-detection